rituximab,ibrutinib
janssen,abbvie
['lymsm']
malibu trial of r + ibr (560 mg dose x 2 yrs) in 1l mzl #17icml
- 45 pts, mostly smzl
- orr 97%, but dor &amp; pfs much lower in nmzl compared to smzl
- 4% afib, 10 d/c, 13 dose reductions smzl benefit is likely from r x 4, nmzl pfs drops off precipitously when ibr stops. #lymsm 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈